Search PubMed⌕ Search

Biomedical subjects

R Ohno

Publications and source records attributed to R Ohno.

391 records · Page 22Linked to original sources
PubMed1976

Blastoid transformation of human lymphocytes cultured with protein-bound polysaccharide preparation, PS-K, in vitro.

The protein-bound polysaccharide preparation, PS-K, isolated from a mushroom, Coriolus versicolor, was found to stimulate human lymphocytes and induce them into blastogenesis in vitro. This stimulatory effect seemed to be nonspecific since lymphocytes from cord blood of newborn babies were also stimulated by PS-K. The highest lymphocyte blastogenesis by PS-K was observed after 5 days in culture.

Cells, Cultured↗
PubMed1976

Effect of protein-bound polysaccharide preparation, PS-K, on the immune response of mice to sheep red blood cells.

The protein-bound polysaccharide preparation, PS-K, was found to potentiate the production of hemolytic plaque-forming cells of spleen and serum hemagglutinin in C57BL/6 mice, when they were immunized with a low dose of sheep red blood cells. PS-K was administered intraperitoneally at a dose of 150 mg/kg daily for 5 days. Ten days later, the mice were immunized with either 4 X 10(8) or 1 X 10(7) sheep red blood cells. Both the number of plaque-forming cells in their spleen and the amount of serum hemagglutinin were significantly higher in the PS-K treated mice when 1 X10(7) sheep red blood cells were used as an immunizing dose.

Animals↗
PubMed1975

Daunorubicin, cytosine arabinoside, 6-mercaptopurine riboside, and prednisolone (DCMP) combination chemotherapy for acute myelogenous leukemia in adults.

Thirty-seven adults with acute myelogenous leukemia (AML) were treated with a combination of daunorubicin, cytosine arabinoside, 6-mercaptopurine riboside, and prednisolone (DCMP) for remission induction. Twenty-three of 37 patients (62.2%) achieved complete remission, three, partial remission and 11, failure. Patients with prior therapy responded as well as patients without it. The median survival time of the patients who received DCMP for their initial remission induction therapy was 10.3 months and that of the patients who obtained complete remission was 17 months. Complete remission occurred in 21 out of 28 patients (75%) less than 40 years old but in only two out of nine patients (22.2%) more than 40 years old. The most common toxic effects were severe myelosuppression and liver function abnormalities. DCMP therapy is an effective remission induction chemotherapy for adults with AML.

Adolescent↗
PubMedDate not supplied

Diverse biological activities of moxa extract and smoke.

Diverse biological activities of moxa extracts and smoke (gas phase) were investigated. Moxa was extracted with hot water (Fr. I), or ethanol (Fr. II), or extracted with hot water after ethanol wash (Fr. III) and then lyophilized to obtain the dried powders. Moxa smoke (containing a lot of gaseous components obtained by burning Moxa) (Fr. IV) was collected into phosphate-buffered saline and quantified spectrophotometrically. These extracts and Moxa smoke showed comparable cytotoxic activity against human oral tumor cell lines (HSC-2, HSG). Human gingival fibroblasts (HGF) were more resistant to any Moxa fractions. Neither of the extracts showed anti-HIV activity. Pretreatment of mice with Fr. I significantly reduced the lethal effect of E. coli infection. All extracts produced radicals under alkaline condition, with a maximum intensity at pH 10.5, and enhanced the radical intensity of sodium ascorbate. It was unexpected that these extracts show significant O2- scavenging activities. These data suggest the medicinal efficacy of Moxa extracts and smoke.

Animals↗